Envista Holdings Corporation (NYSE:NVST) Given Average Rating of “Hold” by Analysts

Envista Holdings Corporation (NYSE:NVST) has been assigned an average rating of “Hold” from the fifteen analysts that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $20.23.

Several equities analysts have recently commented on the stock. UBS Group reduced their price target on shares of Envista from $21.00 to $18.00 and set a “neutral” rating on the stock in a research report on Monday, May 5th. Baird R W raised shares of Envista from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 27th. Bank of America cut their target price on shares of Envista from $26.00 to $23.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Evercore ISI raised their price target on shares of Envista from $19.00 to $23.00 and gave the company an “outperform” rating in a research note on Wednesday, July 9th. Finally, Piper Sandler dropped their price target on shares of Envista from $18.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 30th.

Envista Stock Performance

Shares of NVST stock opened at $19.77 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.82 and a current ratio of 2.12. Envista has a one year low of $14.22 and a one year high of $23.00. The company’s 50-day simple moving average is $18.87 and its 200-day simple moving average is $18.53. The stock has a market capitalization of $3.35 billion, a price-to-earnings ratio of -3.03, a PEG ratio of 1.25 and a beta of 1.00.

Envista (NYSE:NVST) last issued its quarterly earnings results on Thursday, May 1st. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.20 by $0.04. Envista had a negative net margin of 44.90% and a positive return on equity of 4.07%. The business had revenue of $616.90 million for the quarter, compared to analysts’ expectations of $608.17 million. During the same quarter last year, the company posted $0.26 earnings per share. The company’s quarterly revenue was down 1.1% compared to the same quarter last year. Equities analysts anticipate that Envista will post 1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its stake in shares of Envista by 1,338.3% during the 1st quarter. GAMMA Investing LLC now owns 33,139 shares of the company’s stock valued at $572,000 after buying an additional 30,835 shares during the period. Two Sigma Advisers LP lifted its position in Envista by 66.6% during the 4th quarter. Two Sigma Advisers LP now owns 47,800 shares of the company’s stock worth $922,000 after acquiring an additional 19,100 shares during the last quarter. Comerica Bank lifted its position in Envista by 8.2% during the 4th quarter. Comerica Bank now owns 121,851 shares of the company’s stock worth $2,350,000 after acquiring an additional 9,248 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Envista by 220.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 47,319 shares of the company’s stock worth $817,000 after acquiring an additional 32,556 shares during the last quarter. Finally, Norges Bank acquired a new position in Envista during the 4th quarter worth $38,052,000.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.